Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Market Price Survey Becomes a Main Issue
July 25, 2005
- SEMINAR
July 25, 2005
- PMDA to Reach 90% of Review Staff Target By Next April
July 25, 2005
- Exclusive Agreements Hinder Industry-Academia Alliances: Dr Hirate of Pfizer
July 25, 2005
- REGULATORY NEWS IN BRIEF
July 25, 2005
- R&D NEWS IN BRIEF
July 25, 2005
- Rozerem Could Reach US Market in Sept. at Earliest: Takeda
July 25, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 25, 2005
- Janssen Pharm. to Revise Marketing System
July 25, 2005
- Overseas Sales Account for 60% of Sales: Toshiba Medical Systems
July 25, 2005
- Toyobo to Expand Life Science Business
July 25, 2005
- Sakura Group Companies to Be Reorganized
July 25, 2005
- BUSINESS NEWS IN BRIEF
July 25, 2005
- MEDICAL DEVICE NEWS IN BRIEF
July 25, 2005
- NEW PRODUCTS
July 25, 2005
- Inhaled Steroids Reduce Medical Costs for Asthma Patients: GSK
July 25, 2005
- MOF to Demand "Large Cut" in Natural Increases in Social Security Spending
July 18, 2005
- REGULATORY NEWS IN BRIEF
July 18, 2005
- Dainippon, Sumitomo Pharm. Gear Up Merger Process
July 18, 2005
- BUSINESS NEWS IN BRIEF
July 18, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…